AbbVie says not to seek faster approval for lung cancer drug
(Reuters) - Drugmaker AbbVie Inc said on Thursday it would not seek accelerated approval for its experimental lung cancer treatment based on the results from a mid-stage study, sending its shares down 6 percent in premarket trading.
from Reuters: Health News http://reut.rs/2G2FF6S
http://bit.ly/2zwRqiM
March 22, 2018
|
Labels:
health,
Reuters: Health News
|
This entry was posted on March 22, 2018
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.